19 October-30 November 2020
The 51st Union World Conference On Lung Health
REGISTER NOW

Sessions

All Sessions
keyboard_arrow_down
keyboard_arrow_down Show filters keyboard_arrow_up Hide filters
  • All Tracks
  • Community Connect
  • Channel 1
  • Channel 2
  • Channel 3
  • Channel 4
  • Channel 5
  • Channel 6
  • Channel 7
  • E-posters
  • Workshops
Channel 2
OA-40-Health and well-being post-TB
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-40-Health and well-being post-TB
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-40-742-24-Comorbidities and all-cause mortality post-TB treatment: a retrospective cohort study of patients previously treated with second line TB drugs in Georgia Emerging evidence suggests that patients formerly treated for tuberculosis (TB) are likely to be at increased risk of morbidity and mortality post-TB. Our study found that post-TB mortality rates were higher among TB survivors with pre-existing comorbidities, including hyperglycemia (i.e.diabetes/pre-diabetes), hepatitis C virus, and human immunodeficiency virus (HIV) co-infection.

Argita Salindri

15:13 - 15:21: OA-40-743-24-TB Sequel project: characteristics of a TB cohort at treatment initiation in four African countries Tuberculosis (TB) is a global health emergency with little known about the long-term sequelae. The TB Sequel cohort aims to describe lung outcomes in African patients. This abstract presents the description of the characteristics of TB patients enroled into the study.

Andrea Rachow

15:21 - 15:29: OA-40-744-24-Lung function post-TB in Malawian adults: a three-year cohort study We followed-up patients three years from complication of tuberculosis (TB) treatment and reviewed patient outcomes including lung function, healthcare-seeking, symptoms and clinical observation. We concluded that, for a subset of the population, post-TB lung disease is a significant consequence of pulmonary TB.


Rebecca Nightingale

15:29 - 15:37: OA-40-745-24-Risk factors associated with recurrent TB: a systematic review and meta-analysis Recurrent tuberculosis (TB) frequency and proportion of re-infections and relapses, vary in different settings. We performed a systematic review and meta-analysis of risk factors associated to recurrent TB, relapses and reinfections among literature since 1980. 

Victor Vega

15:37 - 15:45: OA-40-746-24-Systematic review and meta-analysis of the association between recurrent TB and HIV infection Tuberculosis (TB) patients with HIV infection may be at a higher risk of recurrent TB than HIV-negative ones. We aimed to review the frequency of recurrent TB and the risk of developing recurrent TB, exogenous reinfection and relapse, according to HIV status among literature since 1980.

Victor Vega

15:45 - 16:20: Q&A


Loading...
Channel 4
SP-46-Subclinical TB disease: lessons and questions from field to lab
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Symposium
mic English
SP-46-Subclinical TB disease: lessons and questions from field to lab
*Please scroll down for more information*
Prevalence surveys suggest that subclinical tuberculosis (TB), which is defined as culture-positive TB disease without reporting TB symptoms, constitutes around half of the undiagnosed disease burden. Policy makers are now looking to understand and address this apparently asymptomatic reservoir to prevent ongoing Mycobacterium tuberculosis transmission in their communities. This symposium will bring expertise across disciplines and the audience together to discuss lessons from past and current symptom-agnostic screening programmes, explore the biological basis for the subclinical TB phenotype and explore how, and how much, asymptomatic individuals contribute to population-level transmission.  

15:00 - 15:05: Introduction

15:05 - 15:15: Subclinical TB disease: what do we know, what do we need to knowIt is becoming clear that a two state latent active paradigm is overly simplistic and limits approaches to tuberculosis (TB) control. In this talk, data will be presented from both a historical systematic review and a contemporary study to provide fresh insight into the subclinical disease state and the heterogeneous kinetics of disease progression. The implication of this for diagnostic and intervention strategies will then be explored.
Hanif Esmail

15:15 - 15:25: Lessons from the field: experiences from a mass X-ray screening programmeOne approach to address subclinical tuberculosis (TB) for a TB care and prevention programme is to employ mass X-ray screening. Until recently, this approach has been employed in a number of countries. Rather than re-invent the wheel, there are valuable insights for countries considering this policy option. This presentation will outline the benefits, costs and political background of the mass X-ray screening in Russia.
Nataliya V Stavitskaya

15:25 - 15:35: Lessons from the lab: what is the biological basis for subclinical TB?Blood-based transcriptional diagnostics have been proposed as tests that may be able to identify those with culture-positive prevalent disease and potentially also predict those who will develop disease in subsequent months. This presentation will highlight insights into this from the recently completed CORTIS trial and discuss the strengths and limitations of this approach as a future tool in the active case finding context and insights into the host response during subclinical phase of disease.
Thomas Scriba

15:35 - 15:45: Lessons from the breath: better predictor of transmission or disease?Tuberculosis (TB) is transmitted by aerosolisation of M.tuberculosis (M.tb). Traditionally we have relied upon spontaneous sputum production as the primary sample for case detection and a proxy for infectiousness. While cough is usually considered the primary driver of aerosolisation facilitating transmission, this dogma is now being challenged, especially in the context of subclinical disease. This presentation will build on recent insights using face masks to capture aerosols in community screening, active case finding and transmission studies, and explore the impact of these findings on the current paradigms around M.tb transmission and what this might mean for testing for clinical and subclinical disease.    
Caroline Williams

15:45 - 15:55: Lessons from the population: how infectious is subclinical TB?One of the key questions around subclinical tuberculosis (TB) remains the contribution to transmission from this asymptomatic, bacteriologically-confirmed population. If cough is absent or limited, how effective is transmission and how do other aspects of subclinical disease affect transmission? To address these questions, the presentation will bring together empirical data on the relative infectiousness of subclinical TB. Through a simple model, the presentation will provide an estimate of the proportion of all population transmission that is due to subclinical TB in Viet Nam, a high burden country with a substantial burden of subclinical TB.
Jon C. Emery

15:55 - 16:20: Q&A session

Loading...
Channel 3
OA-41-TB detection and treatment in mothers and children
event_note
Loading...
query_builder 15:00 - 16:20 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Oral Abstract session
mic English
OA-41-TB detection and treatment in mothers and children
*Please scroll down for more information*


15:00 - 15:05: Introduction


15:05 - 15:13: OA-41-747-24-Increasing active TB case detection rate among children in nine sub-Saharan countries: the CaP-TB Intervention We demonstrate that a comprehensive intervention, which includes paediatric-specific, systematic symptom screening of children in waiting areas of various health facility entry points, increased access to Xpert MTB/RIF testing. It also intensified household contact investigation and significantly improves, both case detection and bacteriological confirmation, for paediatric TB.

Jean-Francois Lemaire

15:13 - 15:21: OA-41-749-24-Role of urban DOTS approach on TB case finding among infertile women in Kabul: a document review Infertility is one of the serious problems for women in Afghanistan that led to mental disorders, in house conflicts, even separation and divorce. The aim of this assessment was to evaluate the outcomes of genital tuberculosis treatment along with anti-infertility treatment on fertility status of women in Kabul city.

Lutfullah Manzoor

15:21 - 15:29: OA-41-750-24-Systematic review of symptom-based screening and added value of chest radiography in screening paediatric contacts for TB in high- incidence countries We conducted a systematic review assessing the concordance between chest radiography and symptom screening to rule out tuberculosis (TB) in household child contacts in high-incidence countries. Results from six articles included in the review suggested that symptom-based screening alone was effective in classifying children unlikely to have TB.

Anca Vasiliu

15:29 - 15:37: OA-41-751-24-A systematic review of Xpert MTB/RIF and Xpert Ultra diagnostic accuracy for detection of active pulmonary TB and rifampicin resistance in children We will discuss results from a systematic review of the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for the diagnosis of Mycobacterium tuberculosis and rifampicin resistance in children using multiple diagnostic specimen types (sputum, gastric aspiration, nasopharyngeal aspiration and stool).

Alexander Kay

15:37 - 15:45: OA-41-752-24-Population pharmacokinetics and potential, new optimised, fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in paediatric patients with TB In 2010, the World Health Orgaization revised the recommended paediatric doses of first line anti-tuberculosis (TB) drugs. We measured rifampicin, isoniazid and pyrazinamide plasma concentrations in 179 HIV-infected and uninfected children aged 0.2-12 years-old. Using model-based estimates of exposure, we suggest a new fixed-dose combination formulation, with revised weight-bands to improve exposures.

Roeland Wasmann

15:45 - 15:53: OA-41-753-24-Pregnancy and birth outcomes in multidrug-resistant TB patients treated with regimens including new and re-purposed drugs We report on incidence of pregnancy, birth and treatment outcomes among multidrug-resistant tuberculosis (TB) patients routinely initiated on treatment regimens containing bedaquiline, delamanid and re-purposed drugs in Pakistan.  Data was collected as a part of the End TB observational study.

Saman Ahmed

15:53 - 16:12: Q&A


Loading...
Channel 7
TBS4A-Innovations in TB therapeutics: plenary session
event_note
Loading...
query_builder 15:00 - 16:22 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS4A-Innovations in TB therapeutics: plenary session
*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

15:00 - 15:03: Introductory note


15:03 - 15:23: Opportunities and risks: using therapeutic TB vaccines to improve cures and shorten treatment for active disease

Gavin Churchyard

15:23 - 15:43: Single-bacilli response to drug exposure within lesional microenvironments: bug-drug interactions within the granuloma and beyond

Joshua Vasquez

15:43 - 16:03: Diversity of Mycobacterium tuberculosis and clinical outcomes of TB. The challenges posed for optimising HDT for TB

Margarida Saraiva

16:03 - 16:22: Live Q&A


Loading...
Channel 7
TBS4B-Innovations in TB therapeutics: oral abstract presentations
event_note
Loading...
query_builder 16:30 - 17:12 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS4B-Innovations in TB therapeutics: oral abstract presentations
*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

16:30 - 16:32: Session introduction


16:32 - 16:40: TBS-OA-13-An empirical modeling approach for regimen development: How to build a winning team.

Natasha Strydom

16:40 - 16:48: TBS-OA-14-The role of respiratory microbiome in early bactericidal activity of anti-tuberculosis therapy and treatment outcome

Wilber Sabiiti

16:48 - 16:56: TBS-OA-15-In silico assessment of adaptive trial design for TB regimen development

Vincent Chang

16:56 - 17:04: TBS-OA-16-Translational platform for predicting clinical outcomes for new combination regimens using pre-clinical and phase I data

Qianwen Wang

17:04 - 17:12: Live Q&A


Loading...
Community Connect
The role of civil society organizations in the social package of care for sustainable people-centered TB services
event_note
Loading...
query_builder 16:30 - 17:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session
card_travel Community Connect
mic English
The role of civil society organizations in the social package of care for sustainable people-centered TB services
This session will describe the key components of a social package of care and sustainable people-centred TB services, and the role that civil society can play. However, there remain a number of barriers to the successful partnership between healthcare systems and civil society. Speakers will highlight such issues facing civil society, and provide examples of how particular organisations have managed to overcome these difficulties. This is an excellent opportunity for civil society to share and learn from examples of best practices in the field, as well as receiving feedback about issues they are facing. This has been a key area of work for the TB Europe Coalition, who have been able to support many of its members in their work with healthcare systems. TBEC members will share their own experience, as well as answering questions from viewers in order to build knowledge and strategies among civil society. 

Yuliia Kalancha, Acting Director for the TB Europe Coalition
Paul Sommerfeld, Chair of the Board for the TB Europe Coalition
Oxana Rucsineanu
Sayohat Hasanova
Safar Naimov
Loading...
Channel 7
TBS4C-Innovations in TB therapeutics: panel discussion
event_note
Loading...
query_builder 17:20 - 18:05 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel TBScience session
mic English
TBS4C-Innovations in TB therapeutics: panel discussion
*Please scroll down for more information*
Tuberculosis (TB) therapeutics research is experiencing a renaissance with an increasing number of new compounds, innovative tools and strategies undergoing evaluation as part of novel regimen development. This is welcome progress as the field seeks to address the long durations of treatment, toxicities, drug–drug interactions and high costs of current therapies. This session will highlight the potential of therapeutic vaccines, innovative tools for regimen development and genomic discoveries with relevance to development of host-directed therapies for curing TB.

17:20 - 17:30: Panel discussion

Gavin Churchyard
Joshua Vasquez
Margarida Saraiva
Amina Jindani
Rada Savic

17:30 - 17:40: Live Q&A

Gavin Churchyard
Joshua Vasquez
Margarida Saraiva
Amina Jindani
Rada Savic

Loading...
Channel 3
Closing session
event_note
Loading...
query_builder 18:15 - 19:15 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Closing Session
mic English
Closing session
*Please scroll down for more information*
Union World Conference closing session
24 October 2020 – 18:15 – 19:15 CEST
The first ever virtual Union World Conference is coming to an end.
During the closing session we announce the winners of The Union Awards. The awards honour outstanding contributions to lung health and are an important and valued way to recognise the work being conducted across the globe. The awards will be announced by Keren Middelkoop, Chair Coordinating Committee of Scientific Activities and Dr Jeremiah Chakaya Muhwa, Chair of the Nominating Committee and Past President.
The Rt Hon The Lord Herbert of South Downs CBE PC will speak on behalf of the Global TB Caucus. RD Marte will share her personal story with us as a lung health survivor.
In closing, The Union’s Executive Director, José Luis Castro, will look back at previous years and President of The Union, Guy Marks, will look towards the future, together with you.

Loading...
Channel 1
SS-10-Role of new age technologies of artificial intelligence and machine learning in pandemic of TB and Covid 19 – lessons learnt
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-10-Role of new age technologies of artificial intelligence and machine learning in pandemic of TB and Covid 19 – lessons learnt
*Please scroll down for more information*
Organised by: DeepTek Inc.

Novel coronavirus disease (COVID-19) and tuberculosis (TB) are two key challenges that have severely unsettled the world. We focus on the role of digital chest X-ray and High-Resolution CT chest for screening.  Artificial Intelligence (AI) enabled, instant triage and smart reporting ensures fast turn-around times for resource constrained units. Innovating TB screening in times of COVID-19 pandemic can help deal with the two challenges in one setting. Expert panelists from leading hospitals, governmental organizations, NGO’s share their valuable experiences to showcase how AI is a force multiplier for public health screening.
Target audience: government bodies, non- profit organizations/ non- government organizations, foundations/trusts, hospitals

18:15 - 18:20: Introduction


18:20 - 18:35: Our experience in COVID-19 diagnosis from Mumbai India using artificial intelligence augmented radiological imaging to improve turnaround time of reporting. Dr Patkar will discuss the role of AI in busy tertiary care setups reorganised into designated COVIDd Care centers due to enhanced number of cases. How Hospitals can benefit by the value add created by AI and enhance patient throughput.

Deepak Patkar

18:35 - 18:50: High volume tertiary care COVID-19 instant triage and response using Machine learning and smart structured reporting Role of AI in Diagnosis of Pandemics and Corona Virus Like scenarios. The Present value of disruptive innovations. Considering the looming health concern of COVID-19, how can AI and Disruptive healthcare innovators partner with hospitals, research organisations and Government work on opportunities for early diagnosis to move beyond assessing the illness by clinical symptoms. AI radiology can deploy the tools and algorithms to encourage early intervention and monitor complications preventing high morbidity. It would be very useful to humanity if the stakeholders in current crisis with present affected population can their clinical data, learnings, knowledge to help co create a fast prototype to market and pre-empt future pandemic panic. Are we mature to share the learnings?

Avinash Nanivadekar

18:50 - 19:05: How resource constrained economies are using low cost imaging and AI for TB screening. Co-testing for TB and COVID-19, is this a reality? The world was already facing the slow pandemic of TB, when COVID-19 stuck. The global target for TB elimination is set at 2030 and India has set the target of TB elimination by 2025. How do these targets match up in the era of COVID-19? Can new age technologies support in keeping these targets intact?

Akash Dey

19:05 - 19:20: Prospects of use of artificial intelligence in national TB elimination programme Services of National TB elimination Programme got impacted due to COVID-19 pandemic in terms of decline in notification etc. NTEP have undertaken various initiatives to reclaim lost notifications including policy of bidirectional screening for TB and COVID simultaneously.
COVID-19 have provided an opportunity to address all respiratory ailments in comprehensive, synergistic fashion. It may augment response, save resources more over may contribute to health system strengthening.
Use of Artificial intelligence in various components of programme specially diagnostics provide an opportunity to deal with TB & COVID in comprehensive manner.
Application of AI in radiological screening for TB, COVID and other respiratory infections is in tandem of broader principles of Pulmonary Approach to Lung Health (PAL) and may significantly contribute to Health system strengthening. It may equip health system for future respiratory outbreaks.

Sandeep Bharaswadkar

19:20 - 19:35: Computer-aided reading (CAR) software for TB screening: learnings from Viet Nam This presentation will highlight the community-based CXR screening which FIT and partners have conducted in Viet Nam and the CAR evaluations which have been conducted with the resultant data.  This will include a landscape analysis for 13 different CAR software, a training and evaluation scheme for a CAR software program to triage normal images away from human read and an assessment of additional/marginal yields of TB from sputum collection based on CAR results.

Andrew Codlin

19:35 - 19:45: Q&A session


Loading...
Channel 2
SS-11-TB in the COVID-19 era in India
event_note
Loading...
query_builder 18:15 - 19:45 | Event time (GMT+2)
query_builder - | Your time (GMT)
place Online Session/Virtual
card_travel Satellite session
mic English
SS-11-TB in the COVID-19 era in India
*Please scroll down for more information*
Organised by: Mylan Pharmaceuticals Pvt. Ltd
COVID-19 pandemic has presented us with a global health crisis. The national programmes to combat TB need to be actively engaged ensuring an effective, rapid response to COVID-19 whilst maintaining TB services. This satellite session discusses relationship between TB/COVID, impact of COVID- 19 on TB management, strategies adopted to mitigate them and how policies need to be shaped considering the dual morbidity of TB and COVID going forward.
Target audience: pulmonologists, infectious disease specialists, c         consultant physicians, programme managers, policy-makers


18:15 - 18:20: Introduction


18:20 - 18:40: Challenges in the management of TB during the pandemic COVID-19 pandemic has had a significant impact in the delivery of various tuberculosis prevention, surveillance, and treatment programmes. Lockdown and public health guidelines have resulted in tough challenges in traditional management of tuberculosis. This talk presents the challenges in the managing TB during the pandemic.

Kuldeep Singh Sachdeva

18:40 - 19:00: Adapting TB services during COVID-19 As the first cases of COVID-19 were identified in India, the provision of essential services in Mumbai (including those for TB/DR-TB), were heavily affected by lockdown regulations and reassignment of health care workers to COVID-19. To ensure continuity of care, TB services were adapted to protect both health care workers and patients, focusing on infection prevention and control measures, screening, linkage to COVID-19 care and the avoidance of non-essential visits. This talk summarizes the main challenges faced during this adaptation of TB services and the proposed solutions.

Vikas Oswal S

19:00 - 19:20: Preparing tertiary TB institute for COVID-19: challenges and Solution It is known that COVID-19 and TB have similar clinical features and presentations. There exist subtle differences between the two disease processes. Early evidence suggests patients with latent TB and established disease have an increased risk of the SARS-CoV-2 infection and predisposition towards developing severe COVID-19 pneumonia. This talk will describe the COVID-19 and TB relationship.

Rupak Singla

19:20 - 19:30: Closing remarks

Digambar Behera

19:30 - 19:45: Q&A session


Loading...
Processing. Please wait.
Loading...